Twin cohort for the study of (pre)clinical Inflammatory Bowel Disease in the Netherlands * The TWIN study

Recruiting

• Conditions: inflammatory bowel disease and Crohn's disease and Ulcerative colitis; 10017969

• Registration Number: NL-OMON53107
• Lead Sponsor: Maag-, Darm- en Leverziekten & Laboratorium voor Translationele Immunologie

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Last Update Posted: 23 April 2024

Recruitment & Eligibility

• Status: Recruiting
• Sex: Not specified
• Target Recruitment: 444

Inclusion Criteria

Inclusion criteria for the IBD-discordant and IBD-concordant twins or multiples:
- Born as a sibling of, either a monozygous or dizygous, twin pair or multiplex
- One or more twin-siblings or multiples are affected with IBD, i.e. CD, UC or
IBD unspecified (self-reported diagnosis, to be confirmed during the study by
clinical, endoscopic or histological reports from the treating physician)
- Age: 16 years and older, In order to be eligible to participate in this
study, a subject must meet all of the following criteria for the unaffected
controls (preferably twins or multiples):
- None of the siblings of the twin are affected with IBD, i.e. CD, UC or IBD
unspecified
- Age: 16 years and older

Exclusion Criteria

A potential subject who meets any of the following criteria will be excluded
from participation in this study:
- No consent to participate in the study.

Study & Design

• Study Type: Observational invasive
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
<p>Comparisons will be made between siblings of twin pairs and between IBD<br /><br>patients and non-IBD controls. Amongst others, changes in immune parameters in<br /><br>the mucosal and peripheral blood compartment, gut and oral microbiome,<br /><br>epithelium and mucus barrier function, and the metabolome will be studied. In<br /><br>addition, correlations between demographic, environmental and nutritional<br /><br>factors will be made, and quality of life an symptom fluctuations prior to or<br /><br>during IBD will be studied. </p><br>

Secondary Outcome Measures

Name	Time	Method
<p>See above. </p><br>